Hep C trial for Biotron
Thursday, 07 August, 2008
Biotron [ASX: BIT] has started Phase Ib/IIa clinical trials of its BIT225 hepatitis C candidate.
The study will enlist 18 hep C positive patients, who will be sorted into two dosage groups and a placebo control group.
The trial is primarily a safety and tolerability study, but determining the pharmacokinetics and effectiveness of the drug are secondary objectives of the trial.
Biotron expects to conclude the trial by the end of the year.
BIT225 targets the p7 protein of HCV, and has demonstrated good antiviral activity in surrogate models of HCV infection. This trial follows on from a successful Phase I trail conducted in healthy volunteers.
Biotron began as the commercialisation arm of the John Curtin School of Medical Research at ANU.
Organoid platform enables closer study of bat-borne viruses
Reconstructing bat organ physiology in the lab lets scientists explore how zoonotic viruses work...
Global study finds 250 genes linked to OCD
Researchers say they have found the genes linked to obsessive compulsive disorder (OCD), after...
TGA approves therapy for paediatric growth hormone deficiency
The TGA has approved SKYTROFA as a treatment for growth failure in children and adolescents aged...
